《股市简讯》中国华领医药暴跌23%创近两个月新低，终止华堂宁与拜耳合作

路透中文11-22

《股市简讯》中<a href="https://laohu8.com/S/00370">国华</a>领医药暴跌23%创近两个月新低，终止华堂宁与拜耳合作

* 专注开发2型糖尿病药物的华领医药2552.HK周五盘初一度暴跌23%至1.2港元，为9月27日以来最低。

* 该公司稍早公布，已向拜耳BAYGn.DE发出书面通知，有意自明年起将开发用于治疗2型糖尿病的首创葡萄糖激酶激活剂华堂宁（dorzagliatin片剂）在中国的商业化责任过渡至该公司。

为支持华堂宁在中国的持续商业销售，该公司可能会寻求其他潜在合作伙伴。

* 香港股市恒生指数.HSI涨0.3%，恒生综合医疗保健业指数.HSCIH升0.08%。（完）

更多股市简讯请点选CN-CMN-HOT

(记者雷美珍；审校张喜良)

((alison.lui@thomsonreuters.com; +852 3462 7749;))

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2485472677?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-22 09:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485472677","market":"us","top_or_hot":-1,"title":"《股市简讯》中国华领医药暴跌23%创近两个月新低，终止华堂宁与拜耳合作","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>《股市简讯》中<a href=\"https://laohu8.com/S/00370\">国华</a>领医药暴跌23%创近两个月新低，终止华堂宁与拜耳合作</title></head><body><p>* 专注开发2型糖尿病药物的华领医药<span>2552.HK</span>周五盘初一度暴跌23%至1.2港元，为9月27日以来最低。</p><p>* 该公司稍早公布，已向拜耳<span>BAYGn.DE</span>发出书面通知，有意自明年起将开发用于治疗2型糖尿病的首创葡萄糖激酶激活剂华堂宁（dorzagliatin片剂）在中国的商业化责任过渡至该公司。</p><p>为支持华堂宁在中国的持续商业销售，该公司可能会寻求其他潜在合作伙伴。</p><p>* 香港股市恒生指数<span>.HSI</span>涨0.3%，恒生综合医疗保健业指数<span>.HSCIH</span>升0.08%。（完）</p><p>更多股市简讯请点选<span>CN-CMN-HOT</span></p><p> (记者 雷美珍；审校 张喜良)</p><p> ((alison.lui@thomsonreuters.com; +852 3462 7749;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《股市简讯》中国华领医药暴跌23%创近两个月新低，终止华堂宁与拜耳合作</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《股市简讯》中国华领医药暴跌23%创近两个月新低，终止华堂宁与拜耳合作\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-22 09:48 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nL4S3MT03R:1><strong>路透中文</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>《股市简讯》中国华领医药暴跌23%创近两个月新低，终止华堂宁与拜耳合作* 专注开发2型糖尿病药物的华领医药2552.HK周五盘初一度暴跌23%至1.2港元，为9月27日以来最低。* 该公司稍早公布，已向拜耳BAYGn.DE发出书面通知，有意自明年起将开发用于治疗2型糖尿病的首创葡萄糖激酶激活剂华堂宁（dorzagliatin片剂）在中国的商业化责任过渡至该公司。为支持华堂宁在中国的持续商业销售，该...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nL4S3MT03R:1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nL4S3MT03R:1","article_id":"2485472677","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485472677","pubTimestamp":1732240139,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"《股市简讯》中国华领医药暴跌23%创近两个月新低，终止华堂宁与拜耳合作* 专注开发2型糖尿病药物的华领医药2552.HK周五盘初一度暴跌23%至1.2港元，为9月27日以来最低。* 该公司稍早公布，已向拜耳BAYGn.DE发出书面通知，有意自明年起将开发用于治疗2型糖尿病的首创葡萄糖激酶激活剂华堂宁在中国的商业化责任过渡至该公司。为支持华堂宁在中国的持续商业销售，该公司可能会寻求其他潜在合作伙伴。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1574":"生物医药B类股","BK1191":"制药","02552":"华领医药-B"},"translate_title":"\"Stock Market Newsletter\" China Hua Medicine plummeted 23% to a new low in nearly two months, terminating cooperation between Huatangning and Bayer","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02552":0.9},"content_text":"《股市简讯》中国华领医药暴跌23%创近两个月新低，终止华堂宁与拜耳合作* 专注开发2型糖尿病药物的华领医药2552.HK周五盘初一度暴跌23%至1.2港元，为9月27日以来最低。* 该公司稍早公布，已向拜耳BAYGn.DE发出书面通知，有意自明年起将开发用于治疗2型糖尿病的首创葡萄糖激酶激活剂华堂宁（dorzagliatin片剂）在中国的商业化责任过渡至该公司。为支持华堂宁在中国的持续商业销售，该公司可能会寻求其他潜在合作伙伴。* 香港股市恒生指数.HSI涨0.3%，恒生综合医疗保健业指数.HSCIH升0.08%。（完）更多股市简讯请点选CN-CMN-HOT (记者 雷美珍；审校 张喜良) ((alison.lui@thomsonreuters.com; +852 3462 7749;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485472677"}